China NT Pharma Group Co Ltd (1011) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Jul, 2017   |   31  Pages   |   GlobalData   |   Format : PDF

Summary

China NT Pharma Group Co Ltd (NT Pharma) is a technology-based pharmaceutical company, which researches, develops, manufactures, and distributes branded and generic pharmaceuticals. The company also promotes and distributes drugs manufactured by third parties. It develops drugs for indications such as cancer; central nervous system disorders; orthopedics; hepatopathy and respiratory disorders. NT Pharma's branded products include Libod and Xi Di Ke for the treatment of various cancers; Miacalcic for bone pain; Shusi, an antipsychotic drug; Zhuo'ao, a respiratory drug, and Songzhi Wan, a traditional Chinese medicine for the treatment of Hepatitis C. The company operates three production bases for chemical drugs, traditional Chinese medicine and bio-chemical drugs through its subsidiaries, Suzhou First, Jiangsu Biopharma and Changsha Pharma. It operates a research and development facility in Beijing. NT Pharma is headquartered in Wanchai, Hong Kong.

China NT Pharma Group Co Ltd (1011) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
China NT Pharma Group Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 11
Partnerships 12
China NT Pharma To Form Joint Venture With Sinopharm 12
Equity Offering 12
China NT Pharma to Raise USD19 Million in Private Placement of Shares 12
China NT Pharma to Raise USD43 Million in Private Placement of Shares 13
NT Pharma Completes IPO Of Common Stock For US$158 Million 14
Debt Offering 15
China NT Pharma Completes Private Placement Of Bonds Due 2016 For US$48 Million 15
Acquisition 16
China NT Pharma Group to Acquire 100% stake in Hunan Kexing Jimeng Pharmaceutical for USD15.27 Million 16
China NT Pharma Completes Acquisition Of Remaining 20% Stake In Suzhou First Pharma For US$9.5 Million 18
China NT Pharma Group Co Ltd - Key Competitors 19
Key Employees 20
Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Mar 21, 2017: China NT Pharma Group Company: Annual Results Announcement For The Year Ended 31 December 2016 22
Aug 18, 2016: China NT Pharma Group Company: Interim Results Announcement For The Six Months Ended 30 June 2016 23
Corporate Communications 28
May 31, 2016: China NT Pharma Group Company Announces Appointment Of Non-executive Director 28
Jan 29, 2016: POSITIVE PROFIT ALERT: China NT Pharma Group Company 29
Product News 30
Jan 26, 2016: NT Pharma will Commence Clinical Research of Lurasidone Hydrochloride 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
China NT Pharma Group Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
China NT Pharma Group Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 11
China NT Pharma To Form Joint Venture With Sinopharm 12
China NT Pharma to Raise USD19 Million in Private Placement of Shares 12
China NT Pharma to Raise USD43 Million in Private Placement of Shares 13
NT Pharma Completes IPO Of Common Stock For US$158 Million 14
China NT Pharma Completes Private Placement Of Bonds Due 2016 For US$48 Million 15
China NT Pharma Group to Acquire 100% stake in Hunan Kexing Jimeng Pharmaceutical for USD15.27 Million 16
China NT Pharma Completes Acquisition Of Remaining 20% Stake In Suzhou First Pharma For US$9.5 Million 18
China NT Pharma Group Co Ltd, Key Competitors 19
China NT Pharma Group Co Ltd, Key Employees 20
China NT Pharma Group Co Ltd, Subsidiaries 21

List of Figures
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
China NT Pharma Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
China NT Pharma Group Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9

China Petrochemicals Report
The China Petrochemicals Report has been researched at source, and features BMI Research's market assessment and independent forecasts for key petrochemicals sub-sectors. The report also analyses the impact of regulatory changes, recent developments and the background macroeconomic outlook and featu
China Oil and Gas Report
BMI View: China's long-term crude oil and liquids output will remain on a firm downtrend as low oil prices slowdown exploration and render certain high-cost mature and unconventional plays uneconomic. Outlook is more positive for natural gas, as the government seeks to increase the share of ga
China Pharmaceuticals and Healthcare Report
BMI View: China will become a leading medical research hub within the Asia Pacific region. This will be largely led by multinational pharmaceutical firms as they seek to tap the large talent pool within the country and develop treatments 'in China, for China'. The local industry, while stil
China Telecommunications Report
BMI View: Operator strategies will continue to chime with the government's directive to drive uptake of wireline broadband and machine-to-machine (M2M) connections. However, this means that even as subscription numbers rise, the prices of basic services will be compressed and operators will derive p
Global and China Lithium Carbonate Industry Report, 2016-2020
Driven by a surge in sales volume of new energy vehicles in China, the upstream material- lithium carbonate was in short supply in the fourth quarter of 2015 with soaring prices. Global lithium carbonate output increased by 12.3% year on year to 202,800 tons in 2015 and is expected to arrive at 244,

Select a Licence type

Custom Research

We are known to provide exact requirements. Try our CUSTOM RESEARCH option and get the exact search result you are searching for.

Contact Us

Postal Address:
808, Real Tech Park, 8th Floor, Sector - 30A, Vashi, Navi Mumbai - 400703 , INDIA .
Telephone: +91 22 27810772, 27810773
Email: info@marketreportsonchina.com
Fax Number: +91 22 27812707

Follow Us On: